HER2-Positive Early Breast Cancer: Future Directions in Risk-Adapted Treatment

In the closing segment, Dr. Neil Iyengar invites Dr. Kelly McCann and Dr. Alison Conlin to reflect on how emerging evidence is shaping the future management of HER2-positive early breast cancer. The faculty discuss the increasing complexity of treatment selection as new therapeutic options become available and emphasize the importance of tailoring therapy according to individual patient risk. Dr. McCann highlights considerations such as central nervous system recurrence risk and the biological differences between hormone receptor-positive and hormone receptor-negative HER2-positive disease, while Dr. Conlin underscores the need for more effective therapies for patients with high-risk disease and continued efforts to de-escalate treatment for lower-risk populations. The panel also discusses the future role of biomarkers in refining patient selection and personalizing treatment strategies. Together, the faculty emphasize that ongoing advances are expanding opportunities to optimize outcomes while further individualizing care for patients with HER2-positive early breast cancer.